Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmark Diagnostics (GNMK)

Genmark Diagnostics (GNMK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments

MONTREAL and CHARLOTTE, N.C., /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular...

MIST : 7.95 (+0.63%)
GNMK : 14.13 (-2.59%)
CBAY : 6.54 (+1.40%)
ONCT : 2.10 (-0.94%)
Are Options Traders Betting on a Big Move in GenMark Diagnostics (GNMK) Stock?

Investors need to pay close attention to GenMark Diagnostics (GNMK) stock based on the movements in the options market lately.

GNMK : 14.13 (-2.59%)
GenMark Diagnostics' ePlex(R) Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens

GNMK : 14.13 (-2.59%)
GenMark Diagnostics' ePlex(R) Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens

GNMK : 14.13 (-2.59%)
Genmark Diagnost Has Returned 21.1% Since SmarTrend Recommendation (GNMK)

SmarTrend identified a Downtrend for Genmark Diagnost (NASDAQ:GNMK) on August 24th, 2020 at $14.66. In approximately 2 weeks, Genmark Diagnost has returned 21.08% as of today's recent price of $11.57....

GNMK : 14.13 (-2.59%)
Cushman & Wakefield Brokers Two Leases with Diagnostics Companies Totaling Over 100,000 SF in San Diego

Cushman & Wakefield (NYSE: CWK) recently announced the firm has brokered two leases comprising over 100,000 square feet (sf) of new occupancy at the NorthPointe and Carlsbad Crossroads projects in Carlsbad...

GNMK : 14.13 (-2.59%)
CWK : 10.54 (-3.83%)
Uptrend Call Working As Genmark Diagnost Stock Rises 30.2% (GNMK)

SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on June 16th, 2020 at $11.76. In approximately 2 months, Genmark Diagnost has returned 30.19% as of today's recent price of $15.31.

GNMK : 14.13 (-2.59%)
GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor(R) SARS-CoV-2 Test

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified the U.S. Food and Drug Administration (FDA) of...

GNMK : 14.13 (-2.59%)
Shares of GNMK Up 35.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on June 16th, 2020 at $11.76. In approximately 2 months, Genmark Diagnost has returned 35.63% as of today's recent price of $15.95.

GNMK : 14.13 (-2.59%)
Diagnostics Begin to Play a Greater Role in the Fight Against Cancer

, /PRNewswire/ -- The diagnostics industry is highly diverse, with a vast number of testing methods already on the market and a consistent flow of new technologies. In fact, diagnostics are no longer...

NTRA : 64.01 (+1.99%)
DGX : 115.23 (-2.47%)
GNMK : 14.13 (-2.59%)
CEMI : 4.68 (-3.11%)
GenMark Diagnostics Reports Second Quarter 2020 Results

GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020.

GNMK : 14.13 (-2.59%)
Uptrend Call Working As Genmark Diagnost Stock Rises 55.5% (GNMK)

SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on June 16th, 2020 at $11.76. In approximately 2 months, Genmark Diagnost has returned 55.53% as of today's recent price of $18.29.

GNMK : 14.13 (-2.59%)
GenMark Diagnostics Announces Commercial Launch of its ePlex(R) Respiratory Pathogen Panel 2 (RP2)

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that its ePlex(R) Respiratory Pathogen 2 (RP2) Panel is now available...

GNMK : 14.13 (-2.59%)
Look for Shares of Genmark Diagnost to Potentially Pullback after Yesterday's 14.74% Rise

Genmark Diagnost (NASDAQ:GNMK) traded in a range yesterday that spanned from a low of $13.27 to a high of $15.81. Yesterday, the shares gained 14.7%, which took the trading range above the 3-day high...

GNMK : 14.13 (-2.59%)
Will GenMark Diagnostics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor of GenMark Diagnostics

GNMK : 14.13 (-2.59%)
GenMark Diagnostics (GNMK) Upgraded to Strong Buy: Here's What You Should Know

GenMark Diagnostics (GNMK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GNMK : 14.13 (-2.59%)
Watch for Genmark Diagnost to Potentially Pullback After Gaining 2.00% Yesterday

Genmark Diagnost (NASDAQ:GNMK) traded in a range yesterday that spanned from a low of $12.03 to a high of $12.73. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

GNMK : 14.13 (-2.59%)
GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has been selected by Vidant Health as its primary provider of rapid diagnostic...

GNMK : 14.13 (-2.59%)
Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally?

Teladoc (TDOC) continues to benefit from constant top-line growth and strategic initiatives, which have been aiding its share price.

REGN : 571.51 (+2.85%)
ACOR : 0.5292 (+2.22%)
GNMK : 14.13 (-2.59%)
TDOC : 215.28 (+6.23%)
The global market for infectious disease rapid diagnostic testing is predicted to grow at a CAGR of 12.36% over the forecast period of 2020-2025

, /PRNewswire/ -- Read the full report: Market Report Coverage - Infectious Disease Rapid Diagnostic Testing • Product – Infectious Disease Diagnostics Assays and Platforms • Technology- Real-Time...

ABT : 104.80 (-1.09%)
GNMK : 14.13 (-2.59%)
HOLX : 65.38 (+0.40%)
LMNX : 24.67 (-3.71%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar